Recalibrating the Demographic Landscape of ME/CFS in the United States
- Aug 25, 2025
- 8 min read
This paper is part of the CYNAERA ME/CFS Library, a growing resource, impacting how MECFS is researched, treated, understood and counted.
By: Cynthia Adinig
Executive Summary
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has long been portrayed in U.S. literature as concentrated among white patients, a view driven by who was studied and who reached specialty care rather than underlying biology (Komaroff et al., 1996; Jason et al., 2004; Dinos et al., 2009). Early tropes such as “yuppie flu” shaped recruitment, messaging, and program design and helped freeze a skewed picture in place (Dinos et al., 2009). Using CYNAERA’s US-CCUC™ framework, we present a corrected profile that includes undocumented immigrants and ancestry-linked biology. The model indicates that roughly half of Americans with ME/CFS are nonwhite, with several groups likely carrying higher true prevalence once baseline intolerance patterns and post viral progression are considered (Jason et al., 2004; Jason et al., 2021; Hornig et al., 2015).
Historical Misclassification
Legacy estimates placed 70–90 percent of diagnosed cases among white patients, reflecting clinic access and recruitment patterns, not population burden (Komaroff et al., 1996; Jason et al., 2004). Black patients presenting with fatigue were more often routed to psychiatric labels, which diverted them from physiologic workups (FitzGibbon et al., 1997; Daugherty et al., 2019). Hispanic and Indigenous patients experienced lower specialist access and geographic barriers, further depressing case capture (Jason et al., 2004; KFF, 2020). These inputs then fed study pipelines that recruited mostly white, middle-class cohorts and reinforced the same signals back to the field (Dinos et al., 2009).
Undocumented populations
Undocumented immigrants are absent from claims-based datasets and underrepresented in surveys, yet many work in physically demanding jobs with high exposure to infections, heat, pollutants, and indoor molds, and often live in housing with dampness and ventilation issues that amplify flares (Bullard et al., 2007; Belcourt et al., 2016). Language barriers and low coverage reduce diagnostic capture, and symptoms are frequently coded as stress related rather than post viral illness (Sacks et al., 2021). CYNAERA’s US-CCUC-U™ overlay adds an estimated 0.40–0.55 million cases nationally to restore this missing population to the U.S. total. A fuller specification is provided in the Comprehensive ME/CFS Overview paper.
Ancestral Nutrition and Biological Consistency
Ancestry and diet add a biologic lens that supports recalibration. Population variations in milk protein tolerance and related gastrointestinal responses are well described, with many African American and Asian American groups showing higher rates of intolerance than white groups (O’Keefe et al., 2015). In pediatric cohorts, food sensitivities and gastrointestinal complaints commonly co-occur with autonomic problems and connective-tissue features, patterns linked to greater risk for post infectious chronic illness (Rowe et al., 2019). The Africa–U.S. crossover diet experiment demonstrated that African Americans placed on a traditional African high-fiber diet rapidly improved gut inflammatory markers, while rural Africans placed on a Westernized diet developed adverse metabolic and inflammatory shifts within weeks, highlighting how diet–ancestry mismatch can drive immune and barrier dysfunction (O’Keefe et al., 2015). Taken together, these signals support upward recalibration for several groups even before accounting for healthcare access effects.
CYNAERA-adjusted Demographic Estimates (2025)
Baseline adults with ME/CFS: ~14.4 million, consistent with the validated US-CCUC™ harmonized range of 15–21.5 million once known gaps are incorporated (Jason et al., 2021; internal CYNAERA harmonization).
Race/Ethnicity | Legacy share (diagnosed) | CYNAERA-adjusted share | Estimated cases |
White (non-Hispanic) | ~75–85% | ~55–60% | ~8.16M |
Black / African American | ~5–7% | ~15–20% | ~2.48M |
Hispanic / Latine | ~6–10% | ~12–15% | ~1.92M |
Asian American / Pacific Islander | ~2–4% | ~5–8% | ~0.92M |
Native American / Alaska Native | <1% | ~3–4% | ~0.50M |
Multiracial / Other | ~1–2% | ~3–5% | ~0.21M |
Undocumented (all groups) | N/A | +0.40–0.55M | ~0.48M |
Note: The core race/ethnicity rows sum to about 14.2 million. Adding the US-CCUC-U™ correction yields roughly 14.6 million. This sits just below the validated national range of 15–21.5 million, which tightens further when LGBTQ+ undercount is incorporated, as outlined in the Comprehensive ME/CFS Overview.
Methods
To generate adjusted estimates, CYNAERA applies US-CCUC-R™ and US-CCUC-U™ to legacy diagnosed counts and population denominators, with weights informed by published undercount ratios, environmental exposure profiles, and care-access indicators (Jason et al., 2004; Jason et al., 2021; Belcourt et al., 2016; KFF, 2020). A fuller specification is published in the Comprehensive ME/CFS Overview.
Post COVID signals confirm the recalibration
Groups that experienced higher COVID-19 hospitalization and mortality also faced lower access to antivirals and post acute care, a pattern consistent with higher post viral chronic illness burden and later detection (CDC, 2021; Khullar et al., 2022). Essential workers, heavily represented by Black, Hispanic, and Asian American adults, absorbed repeated exposures with limited recovery time (BLS, 2020). Pollution and damp-housing clusters overlap with neighborhoods that already carry higher inflammatory load, reinforcing risk for post infectious syndromes (Tessum et al., 2021; Belcourt et al., 2016). These signals match the upward adjustments in the US-CCUC model.
Why This Matters
Research
Trial cohorts that mirror only legacy clinic populations risk missing biology that is common outside those cohorts; inclusive sampling improves biomarker discovery and response profiling (Hornig et al., 2015; Natelson et al., 2020).Policy. Disability adjudication, surveillance, and funding allocation require credible baselines that include undocumented and hard-to-sample groups (KFF, 2020).
Clinical practice
Embedding ME/CFS screening and PEM recognition in primary care increases accurate capture for patients who formerly received stress or mood labels (Rowe et al., 2019; FitzGibbon et al., 1997).
Global link
CYNAERA’s Global-CCUC™ applies the same tiered logic internationally, weighting prevalence by diagnostic capture, environmental burden, social supports for rest, clinical awareness, and pandemic history, with country-level ranges reported separately. A fuller specification is published in the CYNAERA Global-CCUC™ white paper.
Conclusion
ME/CFS in the United States spans every community. The pattern that emerged in early studies reflected access and recruitment, not biology. By restoring undocumented populations to the count and by integrating ancestry-linked biology alongside published undercount signals, CYNAERA’s US-CCUC™ model brings the national picture closer to reality. The practical path forward is clear. Build studies and clinics around who is actually sick, not only who arrived at specialty centers in the past. Align surveillance and program design to current burden. Retire outdated baselines, and plan with numbers that reflect real-world ME/CFS dynamics.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Belcourt, A., et al. (2016). Environmental exposures and health disparities in Native American communities. Environmental Health Perspectives, 124(10), 1476–1483.
Bullard, R. D., et al. (2007). Toxic wastes and race at twenty: 1987–2007. Environmental Justice, 1(1), 1–10.
CDC. (2021). COVID-19 hospitalization and death by race and ethnicity. https://www.cdc.gov/coronavirus/2019-ncov/covid-data
Daugherty, S. L., et al. (2019). Racial disparities in diagnostic evaluation of chronic fatigue. Journal of Health Disparities Research and Practice, 12(3), 45–56.
Dinos, S., et al. (2009). A systematic review of chronic fatigue syndrome: Do not assume it is depression. British Journal of Psychiatry, 195(5), 395–400.
FitzGibbon, E. J., et al. (1997). Racial differences in patients with chronic fatigue syndrome. Journal of General Internal Medicine, 12(4), 211–216.
Hornig, M., et al. (2015). Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Science Advances, 1(1), e1400121.
Jason, L. A., et al. (2004). A community-based study of chronic fatigue syndrome among different racial/ethnic groups. Ethnicity & Disease, 14(2), 247–253.
Jason, L. A., et al. (2021). Estimating prevalence, demographics, and costs of ME/CFS using large-scale claims data. Fatigue: Biomedicine, Health & Behavior, 9(1), 1–13.
Kaiser Family Foundation (KFF). (2020). Health insurance coverage by race and ethnicity. https://www.kff.org
Khullar, D., et al. (2022). Racial and ethnic disparities in access to COVID-19 treatments. Health Affairs, 41(2), 234–241.
Komaroff, A. L., et al. (1996). Health status in patients with chronic fatigue syndrome 10 years later. American Journal of Medicine, 101(3), 281–290.
Natelson, B. H., et al. (2020). Clinical trials in myalgic encephalomyelitis/chronic fatigue syndrome: Current status and future directions. Journal of Translational Medicine, 18(1), 1–10.
O’Keefe, S. J., et al. (2015). Fat, fibre and cancer risk in African Americans and rural Africans. Nature Communications, 6, 6342.
Rowe, P. C., et al. (2019). Diagnosis and management of ME/CFS in children. Pediatrics, 144(5), e20191527.
Sacks, T. K., et al. (2021). Medical gaslighting and patient-reported harm. Social Science & Medicine, 273, 113756.
Tessum, C. W., et al. (2021). PM2.5 sources disproportionately affect people of color. Environmental Science & Technology, 55(8), 4711–4722.
Comments